Search Results - "Haß, Bastian"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Quality of INR control and outcomes following venous thromboembolism by Gallagher, Arlene M, de Vries, Frank, Plumb, Jonathan M, Haß, Bastian, Clemens, Andreas, van Staa, Tjeerd-Pieter

    Published in Clinical and applied thrombosis/hemostasis (01-07-2012)
    “…The objective of this study was to evaluate the pattern of anticoagulation after venous thromboembolism (VTE) in actual clinical practice. This study used the…”
    Get more information
    Journal Article
  2. 2

    Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach by Jürgensen, Jan Steffen, Arns, Wolfgang, Haβ, Bastian

    Published in The European journal of health economics (01-02-2010)
    “…Background The choice of immunosuppression regimen is of paramount importance for outcomes and cost of renal transplantation. We compared the…”
    Get full text
    Journal Article
  3. 3

    Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management by Hass, Bastian, Pooley, Jayne, Harrington, Adrian E, Clemens, Andreas, Feuring, Martin

    Published in Thrombosis journal (31-12-2012)
    “…Effective treatment of venous thromboembolism (VTE) strikes a balance between prevention of recurrence and bleeding complications. The current standard of care…”
    Get full text
    Journal Article
  4. 4

    Cost-Effectiveness of Strong Opioids Focussing on the Long-Term Effects of Opioid-Related Fractures: A Model Approach by Haß, Bastian, Lungershausen, Juliane, Hertel, Nadine, Nautrup, Barbara Poulsen, Kotowa, Wioletta, Liedgens, Hiltrud

    Published in The European journal of health economics (01-07-2009)
    “…Opioid analgesics are known to impact on the central nervous system (CNS). These CNS side effects, such as dizziness and confusion, have been shown to lead to…”
    Get full text
    Journal Article
  5. 5

    Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory by Beck, Hartmut, Härter, Michael, Haß, Bastian, Schmeck, Carsten, Baerfacker, Lars

    Published in Drug discovery today (01-06-2022)
    “…•Bayer celebrates its long history in small molecule drug discovery.•Small molecule drugs have always played a major role in the progress of medicine.•Small…”
    Get full text
    Journal Article
  6. 6

    Health technology assessment and its role in the future development of the Indian healthcare sector by Hass, Bastian, Pooley, Jayne, Feuring, Martin, Suvarna, Viraj, Harrington, Adrian E

    Published in Perspectives in clinical research (01-04-2012)
    “…Public expenditure on healthcare in India is low by international comparison, and access to essential treatment pushes many uninsured citizens below the…”
    Get full text
    Journal Article
  7. 7

    Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? by Pacou, Maud, Basso, Federica, Gore, Charles, Hass, Bastian, Taieb, Vanessa, Cognet, Magali, Pol, Stanislas

    “…OBJECTIVESThe objectives of this study were to identify and quantify the factors driving patient and physician preferences for treatments of genotype 1…”
    Get full text
    Journal Article
  8. 8

    Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review by Brennan, Victoria K, Mauskopf, Josephine, Colosia, Ann D, Copley-Merriman, Catherine, Hass, Bastian, Palencia, Roberto

    “…A systematic review identified studies eliciting utility decrements from myocardial infarction (MI) and stroke in patients with Type 2 diabetes mellitus (T2DM)…”
    Get more information
    Journal Article
  9. 9

    Modeling hard clinical end-point data in economic analyses by Kansal, Anuraag R, Zheng, Ying, Palencia, Roberto, Ruffolo, Antonio, Hass, Bastian, Sorensen, Sonja V

    Published in Journal of medical economics (01-11-2013)
    “…The availability of hard clinical end-point data, such as that on cardiovascular (CV) events among patients with type 2 diabetes mellitus, is increasing, and…”
    Get more information
    Journal Article
  10. 10

    Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling by Brennan, Victoria K, Colosia, Ann D, Copley-Merriman, Catherine, Mauskopf, Josephine, Hass, Bastian, Palencia, Roberto

    Published in Journal of medical economics (01-07-2014)
    “…To identify cost estimates related to myocardial infarction (MI) or stroke in patients with type 2 diabetes mellitus (T2DM) for use in economic models. A…”
    Get more information
    Journal Article